WLWendy Lim

Wendy Lim

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Wendy Lim has a total of 161 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • In adults with acute VTE, apixaban vs. rivaroxaban reduced clinically relevant bleeding at 3 mo

    by Siraj Mithoowani, Wendy Lim

    GIM/FP/GP: [Formula: see text] Hematology: [Formula: see text].

  • Open Access

    External Validation of the JAKPOT Score for Diagnosing JAK2-Positive Erythrocytosis: A Retrospective Cohort Study

    by Justin Bruni Senecal, Yasmine Madan, Rabia Tahir, Sabina Rajkumar, Wendy Lim, Mark Crowther, Siraj Mithoowani

    Background/Objectives: Erythrocytosis is a common laboratory abnormality affecting approximately 4% of males and 0.4% of females. The JAKPOT score was recently developed to differentiate primary from secondary erythrocytosis without molecular testing. JAKPOT+ patients meet any of the following criteria: erythrocytes > 6.45 × 1012/L, platelets > 350 × 109/L, or neutrophils > 6.2 × 109/L. We aimed to validate this score and identify predictors of JAK2-positive erythrocytosis in a retrospective cohort. Methods: We identified 213 patients (50 female, mean age 57 years) with undifferentiated erythrocytosis, serum erythropoietin (EPO) and JAK2 molecular testing (V617F or exon 12) at a tertiary care center in Hamilton, Canada, between 2017 and 2022. Charts were manually reviewed for laboratory data, comorbidities, demographics, and medications. We evaluated the diagnostic accuracy of EPO, JAKPOT, and a combination of low EPO and JAKPOT (EPO-JAKPOT) for predicting JAK2 mutant erythrocytosis. Multivariate logistic regression analysis was performed to detect predictors of JAK2 mutant erythrocytosis. Results: Forty patients (19%) had JAK2 mutations. Older age (p < 0.01), higher platelet count (p < 0.01), and lower EPO (p < 0.01) were associated with JAK2 mutant erythrocytosis in a multivariate analysis. JAKPOT+ status had a sensitivity of 0.88 (95% CI, 0.73–0.94). Combining low EPO or JAKPOT+ status into a new score (EPO-JAKPOT) increased sensitivity to 0.95 (95% CI, 0.83–0.98). Restricting JAK2 testing to only EPO-JAKPOT+ patients would have led to 55% fewer molecular tests in our cohort. Conclusions: The EPO-JAKPOT score shows promise in excluding JAK2 mutant erythrocytosis without molecular testing, but further prospective validation is warranted.

  • Top Cited Papers
    Open Access

    Transfusion of Fresh Frozen Plasma and Platelets in Critically Ill Adults

    by Angel Coz Yataco, Israa Soghier, Paul C. Hébert, Emilie Belley-Cote, Margaret Disselkamp, David Flynn, Karin Halvorson, Jonathan M. Iaccarino, Wendy Lim, Christina C. Lindenmeyer, et al.


  • Open Access

    A Case of Methemoglobinemia and Hemolysis from Sodium Chlorite Ingestion

    by Jessica Liu, Matthew Patel, Marisa Vigna, Mark Keith Hewitt, Wendy Lim

    Sodium chlorite is a household and industrial cleaning agent that can cause oxidative stress leading to methemoglobinemia and severe hemolysis when ingested. There is a scarcity of published literature reporting this in humans. We report a case of intentional sodium chlorite ingestion for homeopathic purposes that resulted in methemoglobinemia and hemolysis, requiring admission to the intensive care unit. Following successful treatment with methylene blue, the patient developed worsening hemolytic activity. Outpatient testing later revealed she was non- glucose-6-phosphate dehydrogenase (G6PD) deficient. Hemolysis precipitated by methylene blue is an underrecognized side effect that can be observed in individuals both with and without G6PD deficiency.


  • Top Cited Papers
    Open Access

    Red Blood Cell Transfusion in Critically Ill Adults

    by Angel O. Coz Yataco, Israa Soghier, Paul C. Hébert, Emilie Belley-Cote, Margaret Disselkamp, David Flynn, Karin Halvorson, Jonathan M. Iaccarino, Wendy Lim, Christina C. Lindenmeyer, et al.


  • Open Access

    Evaluation of a diagnostic platelet aggregation test strategy for platelet rich plasma samples with low platelet counts

    by Rahaf Mahmoud Altahan, Natalie Mathews, Alex Bourguignon, Subia Tasneem, Donald M. Arnold, Wendy Lim, Catherine P. M. Hayward

    Introduction: Light transmission aggregometry (LTA) is important for diagnosing platelet function disorders (PFD) and von Willebrand disease (VWD) affecting ristocetin‐induced platelet aggregation (RIPA). Nonetheless, data is lacking on the utility of LTA for investigating thrombocytopenic patients and platelet rich plasma samples with low platelet counts (L‐PRP). Previously, we developed a strategy for diagnostic LTA assessment of L‐PRP that included: (1) acceptance of referrals/samples, regardless of thrombocytopenia severity, (2) tailored agonist selection, based on which are informative for L‐PRP with mildly or severely low platelet counts, and (3) interpretation of maximal aggregation (MA) using regression‐derived 95% confidence intervals, determined for diluted control L‐PRP (C‐L‐PRP).Methods: To further evaluate the L‐PRP LTA strategy, we evaluated findings for a subsequent patient cohort.Results: Between 2008 and 2021, the L‐PRP strategy was applied to 211 samples (11.7% of all LTA samples) from 192 unique patients, whose platelet counts (median [range] × 109/L) for blood and L‐PRP were: 105 [13–282; 89% with thrombocytopenia] and 164 [17–249], respectively. Patient‐L‐PRP had more abnormal MA findings than simultaneously tested C‐L‐PRP (p‐values n = 181), L‐PRP LTA uncovered significant aggregation abnormalities in 45 (24.9%), including 18/30 (60%) with 9 platelets/L L‐PRP, and ruled out PFD, and VWD affecting RIPA, in others. The L‐PRP LTA strategy helped diagnose VWD affecting RIPA, Bernard Soulier syndrome, familial platelet disorder with myeloid malignancy, suspected ITGA2B/ITGB3‐related thrombocytopenia, and acquired PFD.Conclusion: Diagnostic LTA with L‐PRP, using a strategy that considers thrombocytopenia severity, is feasible and informative.


  • Open Access

    Cost-effectiveness of diagnostic strategies for venous thromboembolism: a systematic review

    by Yuan Zhang, Housne A. Begum, Himmat Grewal, Itziar Etxeandia-Ikobaltzeta, Gian Paolo Morgano, Rasha Khatib, Robby Nieuwlaat, Chengyi Ding, Wojtek Wiercioch, Reem A. Mustafa, et al.

    Guideline developers consider cost-effectiveness evidence in decision making to determine value for money. This consideration in the guideline development process can be informed either by formal and dedicated economic evaluations or by systematic reviews of existing studies. To inform the American Society of Hematology guideline on the diagnosis of venous thromboembolism (VTE), we conducted a systematic review focused on the cost-effectiveness of diagnostic strategies for VTE within the guideline scope. We systematically searched Medline (Ovid), Embase (Ovid), National Health Service Economic Evaluation Database, and the Cost-effectiveness Analysis Registry; summarized; and critically appraised the economic evidence on diagnostic strategies for VTE. We identified 49 studies that met our inclusion criteria, with 26 on pulmonary embolism (PE) and 24 on deep vein thrombosis (DVT). For the diagnosis of PE, strategies including d-dimer to exclude PE were cost-effective compared with strategies without d-dimer testing. The cost-effectiveness of computed tomography pulmonary angiogram (CTPA) in relation to ventilation-perfusion (V/Q) scan was inconclusive. CTPA or V/Q scan following ultrasound or d-dimer results could be cost-effective or even cost saving. For DVT, studies supporting strategies with d-dimer and/or ultrasound were cost-effective, supporting the recommendation that for patients at low (unlikely) VTE risk, using d-dimer as the initial test reduces the need for diagnostic imaging. Our systematic review informed the American Society of Hematology guideline recommendations about d-dimer, V/Q scan and CTPA for PE diagnosis, and d-dimer and ultrasound for DVT diagnosis.


  • Open Access

    How to write a guideline: a proposal for a manuscript template that supports the creation of trustworthy guidelines

    by Robby Nieuwlaat, Wojtek Wiercioch, Jan L. Brozek, Nancy Santesso, Robert Kunkle, Pablo Alonso-Coello, David R. Anderson, Shannon M. Bates, Philipp Dahm, Alfonso Iorio, et al.

    Trustworthy health guidelines should provide recommendations, document the development process, and highlight implementation information. Our objective was to develop a guideline manuscript template to help authors write a complete and useful report. The McMaster Grading of Recommendations Assessment, Development and Evaluation Centre collaborated with the American Society of Hematology (ASH) to develop guidelines for the management of venous thromboembolism. A template for reporting the guidelines was developed based on prior approaches and refined using input from other key stakeholders. The proposed guideline manuscript template includes: (1) title for guideline identification, (2) abstract, including a summary of key recommendations, (3) overview of all recommendations (executive summary), and (4) the main text, providing sufficient detail about the entire process, including objectives, background, and methodological decisions from panel selection and conflict-of-interest management to criteria for updating, as well as supporting information, such as links to online (interactive) tables. The template further allows for tailoring to the specific topic, using examples. Initial experience with the ASH guideline manuscript template was positive, and challenges included drafting descriptions of recommendations involving multiple management pathways, tailoring the template for a specific guideline, and choosing key recommendations to highlight. Feedback from a larger group of guideline authors and users will be needed to evaluate its usefulness and refine. The proposed guideline manuscript template is the first detailed template for transparent and complete reporting of guidelines. Consistent application of the template may simplify the preparation of an evidence-based guideline manuscript and facilitate its use.


  • Open Access

    A systematic review of the association between anti-β-2 glycoprotein I antibodies and APS manifestations

    by Debbie Jiang, Wendy Lim, Mark Crowther, David Garcia

    Anti-β-2 glycoprotein I antibodies (anti-B2GPI) are often cited as the major pathogenically relevant antibody in antiphospholipid syndrome (APS), but it is unclear if there is clinical evidence to support this theory. We performed a systematic review to determine if immunoglobulin G anti-B2GPI positivity was independently associated with thrombotic and/or obstetric manifestations of APS. We searched MEDLINE, EMBASE, The Cochrane Library, and clinicaltrials.gov electronic databases through April 2020 for prospective studies that met prespecified design criteria. Of 4758 articles identified through computer-assisted search, 4 studies examining obstetric outcomes and 2 studies examining thrombotic outcomes were included for qualitative assessment. The presence of anti-B2GPI had only a weak independent association with thrombosis and was, at best, inconsistently associated with obstetric complications. A quantitative assessment could not be performed because of study heterogeneity. The overall quality of the evidence was very low. Although anti-B2GPI are commonly thought to mediate APS manifestations, clinical evidence is lacking with very low-quality data to support a weak association with thrombosis.